Mirati seeks needle move in NSCLC with sitravatinib

Shares of Mirati Therapeutics Inc. doubled at their opening Friday morning and spiked to a 15-month high of $12.40 on word that the combination of the company's TKI, sitravatinib, with Opdivo showed three confirmed PRs in the first 11 evaluable patients with NSCLC who had progressed following checkpoint therapy.